Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Carnaxide – page 20

674 clinical trials in Carnaxide, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Carnaxide at a glance
674
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

674 trials in Carnaxide

Open in trial search

Colitis ulcerative+1

Recruiting

Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Hypertonic bladder

Not yet recruiting

Safety and Efficacy of Intravesical Clostridium botulinum Neurotoxin Type A (150 kD) for Idiopathic Overactive Bladder in Women

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:IncobotulinumtoxinA
  • Sponsor:Vensica Medical Ltd.

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Alogliptin
  • Sponsor:Tecnimede-Sociedade Tecnico-Medicinal S.A.

Aortic valve stenosis

Not yet recruiting

A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ataciguat
  • Sponsor:Kardigan Inc.

Psoriatic arthropathy

Not yet recruiting

A study to evaluate the long-term safety and effectiveness of sonelokimab in patients with psoriatic arthritis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Parkinson's disease

Not yet recruiting

A study to test if BHV-8000 is effective and safe for adults with early Parkinson's disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ioflupane (123I)
  • Sponsor:Biohaven Therapeutics Ltd.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Carnaxide

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on atherosclerotic cardiovascular disease and heart conditions, including trials evaluating new treatments for hypertrophic cardiomyopathy and pediatric heart failure.

  • Cardiovascular Disease Prevention
  • Heart Failure Management
  • Atrial Fibrillation Treatment

Research aims to reduce major cardiovascular events and improve patient outcomes through novel therapeutic approaches.

02 Nephrology Studies

Comprehensive research into kidney disorders, with a focus on IgA Nephropathy and innovative treatments for chronic kidney disease. Multiple trials are investigating new therapeutic options for patients with various forms of kidney dysfunction.

  • Kidney Transplantation
  • Lupus Nephritis
  • Glomerular Diseases

Studies aim to improve kidney function and reduce disease progression in patients with various renal conditions.

03 Metabolic Disorders

Advanced research targeting hypertriglyceridemia and related metabolic conditions. Studies focus on novel treatments for patients with severe metabolic disorders and associated cardiovascular risks.

  • Lipid Management
  • Secondary Hyperparathyroidism
  • Metabolic Disease Complications

Investigations concentrate on developing targeted therapies to address complex metabolic disorders and their complications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.